Research Article

Antibacterial and Antibiotic-Modifying Activity of Methanol Extracts from Six Cameroonian Food Plants against Multidrug-Resistant Enteric Bacteria

Joachim K. Dzotam and Victor Kuete

Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon

Correspondence should be addressed to Victor Kuete; kuetevictor@yahoo.fr

Received 20 March 2017; Revised 30 May 2017; Accepted 18 July 2017; Published 20 August 2017

Academic Editor: Gail B. Mahady

Copyright © 2017 Joachim K. Dzotam and Victor Kuete. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present work was designed to investigate the antibacterial activities of methanol extracts from six Cameroonian edible plants and their synergistic effects with some commonly used antibiotics against multidrug-resistant (MDR) Gram-negative bacteria expressing active efflux pumps. The extracts were subjected to qualitative phytochemical screening and the microdilution broth method was used for antibacterial assays. The results of phytochemical tests indicate that all tested crude extracts contained polyphenols, flavonoids, triterpenes, and steroids. Extracts displayed selective antibacterial activities with the minimal inhibitory concentration (MIC) values ranging from 32 to 1024 $\mu\text{g/mL}$. The lowest MIC value (32 $\mu\text{g/mL}$) was recorded with *Coula edulis* extract against *E. coli* AG102 and *K. pneumoniae* K2 and with *Mangifera indica* bark extract against *P. aeruginosa* PA01 and *Citrus sinensis* extract against *E. coli* W3110 which also displayed the best MBC (256 $\mu\text{g/mL}$) value against *E. coli* ATCC8739. In combination with antibiotics, extracts from *M. indica* leaves showed synergistic effects with 75% (6/8) of the tested antibiotics against more than 80% of the tested bacteria. The findings of the present work indicate that the tested plants may be used alone or in combination in the treatment of bacterial infections including the multidrug-resistant bacteria.

1. Introduction

The discovery of antibiotics has inevitably fostered the development and emergence of resistances in bacteria, regardless of the mechanism of action of the antibiotic involved. For decades, and in order to reduce the development and epidemic spread of resistance, physicians and scientists have called for appropriate use of antibiotics [1]. Prudent use of antibiotics in humans demands that physicians establish that a bacterial infection is responsible for the patient's symptoms before an antibiotic prescription is made. By contrast, in agriculture, antibiotics are used in the absence of acute infection [2]. Bacteria faced with this fierce struggle against them have developed several mechanisms of resistance against antimicrobial agents whose main ones include enzymatic inactivation [3], modification of the drug target(s), and reduction of intracellular drug concentration by changes in membrane permeability or by the overexpression of efflux

pumps [4]. With respect to efflux pumps, they provide a self-defense mechanism by which antibiotics are actively removed from the cell. For antibacterials, this results in sublethal drug concentrations at the active site that in turn may predispose the organism to the development of high-level target-based resistance [5]. In this way, efflux pumps inevitably become targets for the research and/or development of new, less toxic, and effective molecules capable, alone or in combination with the usual antibiotics, of effectively fighting infections involving multidrug-resistant pathogens. Medicinal plants in general and food plants in particular have been used for centuries to cure ailments of man. Today, there is a real revival of interest in these almost-exploited sources [6] of molecules whose pharmacological efficacy is no longer to be demonstrated [7]. The present work was designed to investigate the in vitro ability of methanol extracts from six Cameroonian edible plants (*Psidium guajava* Linn., *Persea americana* Mill., *Camellia sinensis* Linn., *Mangifera indica*

Linn., *Coula edulis* Baill., and *Citrus sinensis* Linn.), to potentiate the activity of some commonly used antibiotics vis-à-vis Gram-negative multidrug-resistant bacteria.

2. Material and Methods

2.1. Plant Material and Extraction. The plant materials used in this work were collected in the period of March to April 2015 in two regions of Cameroon and included leaves and bark of *M. indica*; fruits, leaves, and bark of *P. guajava*; leaves and bark of *P. americana* collected at Koung-Khi division (West Region); leaves of *C. sinensis* and the fruits of *C. sinensis* collected at Menoua division (West Region); and nuts of *C. edulis* collected at Mungo division (Littoral Region). The plants were identified at the National Herbarium (Yaounde, Cameroon) where voucher specimens were deposited under the reference numbers (Table 1). Each plant sample was cleaned and air-dried and the powder (300 g) was extracted with methanol (MeOH, 1 L) for 48 h at room temperature. The extract was then concentrated under reduced pressure to give residues which constituted the crude extract. All extracts were then kept at 4°C until further use.

2.2. Preliminary Phytochemical Investigations. The major phytochemical classes such as alkaloids (Dragendorff's and Mayer's tests), triterpenes (Liebermann-Burchard's test), flavonoids (aluminum chloride test), anthraquinones (Borntrager's test), polyphenols (ferric chloride test), sterols (Salkowski's test), coumarins (lactone test), saponins (foam test), and tannins (gelatin test) (Table 2) were investigated according to the commonly described phytochemical methods [43, 44].

2.3. Bacteria Strains and Culture Media. The studied bacteria strains included reference (from American Type Culture Collection) and clinical (Laboratory collection) strains of *Escherichia coli*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Providencia stuartii*, and *Pseudomonas aeruginosa*. Their bacterial features were previously reported [45, 46]. They were maintained on agar slant at 4°C and subcultured on a fresh appropriate agar plates 24 h prior to any antimicrobial test. Mueller-Hinton Agar (MHA) was used for the activation of bacteria, while Mueller-Hinton Broth (MHB) was used for the MIC determinations.

2.4. Chemicals for Antimicrobial Assays. The reference antibiotics used in the present work included tetracycline (TET), cefepime (CEP), ciprofloxacin (CIP), streptomycin (STP), chloramphenicol (CHL), ampicillin (AMP), erythromycin (ERY), and kanamycin (KAN), all provided by Sigma-Aldrich, St Quentin Fallavier, France. *p*-Iodonitro-tetrazolium (INT) chloride and phenylalanine-arginine- β -naphthylamide (PA β N) were used as microbial growth indicator and efflux pumps inhibitor (EPI), respectively [47].

2.5. Bacterial Susceptibility Determination. Rapid INT colorimetric assay [47] with some modifications [48] was used to determine the minimal inhibitory concentrations (MIC)

of the plant extracts and those of reference antibiotics (RA) against the studied bacteria. The test samples and RA were first of all dissolved in DMSO/Mueller-Hinton Broth (MHB). The final concentration of DMSO was lower than 2.5% and did not affect the microbial growth [49]. The solution obtained was then added to Mueller-Hinton Broth and serially diluted twofold (in a 96-well microplate). One hundred microliters (100 μ L) of inoculum 1.5×10^6 CFU/mL prepared in appropriate broth was then added [48, 50]. The plates were covered with a sterile plate sealer, then agitated to mix the contents of the wells using a plate shaker, and incubated at 37°C for 18 h. The assay was repeated thrice. Wells containing adequate broth, 100 μ L of inoculum, and DMSO to a final concentration of 2.5% served as negative control. The MIC of samples was detected after 18 h incubation at 37°C, following addition (40 μ L) of 0.2 mg/mL of INT and incubation at 37°C for 30 min. Viable bacteria reduced the yellow dye to pink. MIC was defined as the sample concentration that prevented the color change of the medium and exhibited complete inhibition of microbial growth [47]. The MBC was determined by adding 50 μ L aliquots of the preparations, which did not show any growth after incubation during MIC assays, to 150 μ L of adequate broth. These preparations were incubated at 37°C for 48 h. The MBC was regarded as the lowest concentration of extract, which did not produce a color change after addition of INT as mentioned above [50].

The role of efflux pumps in the susceptibility of Gram-negative bacteria to *M. indica*, *C. edulis*, *C. sinensis*, leaves from *P. guajava*, *P. americana*, and *C. sinensis*, and crude extracts was evaluated by testing them in the presence of an efflux pump inhibitor (EPI), the PA β N (at 30 μ g/mL) against fifteen selected MDR phenotypes (*E. coli* AG100A, AG102, and AG100ATet, *E. aerogenes* EA289, EA27, EA298, and CM64, *K. pneumoniae* KP55 and KP63, *E. cloacae* BM47, BM67, and ECCI69, *P. aeruginosa* PA124, and *P. stuartii* NAE16 and PS2636).

To evaluate the potentiating effect of tested extracts, a preliminary combination at their subinhibitory concentrations (MIC/2, MIC/4, MIC/8, and MIC/16) with antibiotics was assessed against *P. aeruginosa* PA124 strain (see Table S1 in Supplementary Material available online at <https://doi.org/10.1155/2017/1583510>). The appropriate subinhibitory concentrations were then selected on the basis of their ability to improve the activity of the maximum antibiotic [51, 52]. These subinhibitory concentrations for selected extracts were further tested in combination with antibiotics against more MDR bacteria. The fractional inhibitory concentration (FIC) of each combination was then calculated as the ratio of MIC of antibiotic in combination versus MIC of antibiotic alone ($\text{MIC}_{\text{Antibiotic in combination}} / \text{MIC}_{\text{Antibiotic alone}}$) and the interpretation made was as follows: synergistic (≤ 0.5), indifferent (1 to 4), or antagonistic (> 4) [53, 54]. All assays were performed in triplicate.

3. Results

3.1. Phytochemical Composition of Plant's Extracts. The results of the phytochemical screening (Table 2) showed that all the tested plant's extracts contain polyphenols, flavonoids,

TABLE 1: Plants used in the present study and evidence of their bioactivities.

Species (family); voucher number*	Traditional uses	Parts used traditionally	Bioactive or potentially bioactive components	Bioactivity of crude extract
<i>Psidium guajava</i> Linn. (Myrtaceae); 2884/SRF/Cam	To treat wounds, lesions, ulcers, diarrhea, cholera, hypertension, and obesity and the control of diabetes mellitus [8]. Anti-inflammatory effect, cough, diabetes, kidney problems, diarrhea, tonic, laxative, antihelminthic [9], conjunctivitis, oral care, and antispasmodic [10].	Leaves, fruits, flowers, bark, and roots	Tannins, flavonoids (myricetin, quercetin, luteolin and kaempferol), essential oils (caryophyllene, nerolidol, β -bisabolene, aromadendrene, p-selinene, α -pinene and 1,8-cineol), triterpenoids (oleanic acid, ursolic acid, catecholic acid, guayavolic acid, maslinic acid, ellagic acid) and β -sitosterol [11]; essential oil: propylbenzene, allyl benzene, and so forth [12].	<i>Antibacterial activity of essential oil: Sa, Sf, Lspp, Esa, Aspp, Ec, Pv, Ea, St, Pa, andKp</i> [12]; <i>antioxidant activity of leaves essential oil</i> [13]. <i>Ethanol extract of leaves: Ec, Kp, Pa, Sa, Ab, MRSA, and VRE</i> [14]; antiproliferative, antiseptic and antifungal activity [9]; <i>ethanol extract of leaves:</i> antioxidant, antitumor, and antibacterial (against <i>Sm, Smt, and Sor</i>) [15].
<i>Persea americana</i> Mill. (Lauraceae); 57756/HNC	Anticancer activity, the food industry has grown tremendous interest in processing this crop and enhancing its value [16]. <i>P. americana</i> leaves' extracts have been used as analgesic, anti-inflammatory, hypoglycaemic, anticonvulsant, antidiabetic, and vasorelaxant [17].	Leaves, fruit, flowers, bark, and roots	<i>Crude leaves extracts:</i> glycosides, alkaloids, tannins, saponins, flavonoids, terpenoids, and steroids [18].	<i>Methanol, chloroform, ethyl acetate, and petroleum ether leaves extracts</i> were tested against <i>Ec, St, Sa, Ca, Pa, and Bs;</i> antioxidant activity [18]; <i>aqueous leaves'</i> extract: anti-inflammatory and analgesic activity [17].
<i>Citrus sinensis</i> Linn. (Rutaceae); 25859/HNC	Treat ailments like constipation, cramps, colic, diarrhea, bronchitis, tuberculosis, cough, cold, obesity, menstrual disorder, angina, hypertension, anxiety, depression, and stress [19]; used to soothe sore throats, indigestion, relieve intestinal gas and bloating and resolve phlegm and as an additive for flavoring to our foods [20].	Leaves, flowers, seeds, peel, fruits, and barks	Polyphenols (caffeic acid, p-coumaric acid, ferulic acid, and sinapinic acid), flavonoids (hesperidin, narirutin, naringin, eriocitrin) [21], essential oil composition: D-limonene, β -myrcene, α -pinene, β -pinene, γ -terpinene, α -terpinolene, α -caryophyllene, copaeane, β -phellandrene [22] and many other constituents.	<i>Ethanol extracts of peels and juice (Q): Sta, Sau, Sm, Ss,Kp, and Ec</i> [20]; <i>ethanol extracts of peels: Sta, Pv, Kp, Ec, Bs, and Pa</i> [23]; <i>crude extract of juice (Q): Ec, Sta, and MRSA</i> [24]; <i>crude extracts from different parts of the plants</i> reduce high blood pressure, respiratory problems, rheumatism [25, 26], and anticancer, antimicrobial, and antioxidant activity [22].
<i>Coula edulis</i> Bail. (Olacaceae); African walnut 22931 SRF/Cam	The stomachic bark decoction is used to treat dysentery in Liberia and the bark powder decoction is used in equatorial Africa to stimulate appetite and counteract anemia [27].	Leaves, stem bark, fruits, and roots	<i>Ethanol extract of leaves, stem bark and roots:</i> alkaloids, flavonoids, tannins, saponins, terpenes, and cardiac glycosides [27].	<i>Ethanol extracts of bark and leaves: Pa, Sa, Ec, St, and Ca</i> [27]. <i>Methanol extract of the bark:</i> antiplasmodial activity [28].

TABLE 1: Continued.

Species (family); voucher number*	Traditional uses	Parts used traditionally	Bioactive or potentially bioactive components	Bioactivity of crude extract
<i>Mangifera indica</i> Linn. (Anacardiaceae); 18646/HNC	Anti-syphilitic, vulnerary, antiemetic, anti-inflammatory, cough, hiccup, hyperdipsia, burning sensation, hemorrhages, haemoptysis, hemorrhoids, wounds, ulcers, diarrhoea, dysentery, pharyngopathy, scorpion sting, wounds, ulcers, anorexia, and dyspepsia [29]. Aiding digestion, blood purification, ensuring regularity, lowering body temperature, strengthening teeth and bones, boosting immune system, enhancing heart function, suppressing aging, deterring food poisoning, fighting virus, and lowering blood sugar levels [40].	Leaves, flowers, barks, roots, stones, and fruits	Carotenoids (provitamin A compound, beta-carotene, lutein, and alpha-carotene), polyphenols [30] such as quercetin, kaempferol, gallic acid, caffeic acid, catechins, tannins, and mangiferin [31].	<i>Mangiferin</i> : anticancer (breast, renal, colon and leukemia cancer cell lines [32, 33]; antidiabetic [34]; antimalarial [35]; <i>methanol and aqueous extracts</i> : <i>Sa</i> , <i>Sp</i> , <i>Pa</i> , <i>Ca</i> , and <i>Ef</i> [36]; <i>Se</i> , <i>Lm</i> , <i>Ec</i> [37]; <i>ethanol and benzene extracts</i> : <i>Pv</i> , <i>Pf</i> , <i>Sfx</i> , <i>Kp</i> , and <i>St</i> [38]; antiamebic [39].
<i>Camellia sinensis</i> Linn. (Theaceae); 43103/HNC		Leaves, stem, bark, and roots	Polyphenols (catechins and their derivatives), methylxanthines (caffeine, theophylline and theobromine), carbohydrates, proteins, free amino acids, vitamins (vitamin C and carotenoids), volatile compounds, lipids, chlorophylls, saponins and inorganic elements (fluorine, manganese and aluminum) [40, 41].	<i>Methanolic extract of leaves</i> : antioxidant activity. These antioxidant properties are beneficial for several chronic diseases related to oxidative stress, including cancer and cardiovascular and neurodegenerative diseases [42].

*HNC: Herbar National du Cameroun, SRF/Cam: Société des Réserves Forestières du Cameroun; Sm: *Streptococcus mutans*; Smt: *Streptococcus mitis*; Sor: *Streptococcus oralis*; Sta: *Staphylococcus aureus*; Sau: *Staphylococcus auricularis*; Ss: *Streptococcus salivarius*; Sp: *Streptococcus pneumoniae*; Kp: *Klebsiella pneumoniae*; Sa: *Streptococcus aureus*; Ec: *Escherichia coli*; Se: *Salmonella enteritidis*; Bs: *Bacillus subtilis*; St: *Salmonella typhi*; Ef: *Enterococcus faecalis*; Sf: *Staphylococcus faecalis*; Pv: *Proteus vulgaris*; MRSA: methicillin-resistant *Staphylococcus aureus*; Pf: *Pseudomonas fluorescens*; Sfx: *Shigella flexneri*; Pa: *Pseudomonas aeruginosa*; Ca: *Candida albicans*; Ea: *Enterobacter aerogenes*; Asp: *Acinetobacter* spp.; VRE: vancomycin-resistant *Enterococcus*; Lspp: *Lactobacillus* spp.; Ab: *Acinetobacter baumannii*; Esa: *Enterococcus aerogenes*; Lm: *Listeria monocytogenes*.

TABLE 2: Extraction yields, aspects, and phytochemical composition of the plant extracts.

Extracts	<i>Psidium guajava</i>			<i>Persea americana</i>		<i>Citrus sinensis</i>	<i>Coula edulis</i>	<i>Mangifera indica</i>		<i>Camellia sinensis</i>
Parts used	Leaves	Bark	Fruits	Leaves	Bark	Peel	Fruits	Leaves	Bark	Leaves
Yield* (%)	5.47	4.17	6.12	5.15	4.47	6.56	7.25	5.36	4.26	5.8
Alkaloids	+	+	–	+	+	+	+	+	+	+
Polyphenols	+	+	+	+	+	+	+	+	+	+
Flavonoids	+	+	+	+	+	+	+	+	+	+
Anthraquinones	–	–	–	+	+	–	+	+	+	–
Coumarins	+	+	+	+	+	+	+	+	+	–
Tannins	+	+	–	+	+	+	+	+	+	+
Triterpenes	+	+	+	+	+	+	+	+	+	+
Sterols	+	+	+	+	+	+	+	+	+	+
Saponins	+	+	–	+	+	+	+	+	+	+

–: absent; +: present; * yield calculated as the ratio of the mass of the obtained methanol extract/mass of the plant powder.

triterpenes, and sterols. The other classes of secondary metabolites were selectively distributed. Also, the extract from the leaves and bark of *P. americana* as well as those of *M. indica* and the extract from *C. edulis* nuts contain all the classes of screened secondary metabolites.

3.2. Antibacterial Activity of the Extracts. The antibacterial activities of plants' extracts alone and in some cases, in the presence of the PA β N on a panel of 29 Gram-negative bacteria, was investigated (Table 3). It appears that *P. guajava* leaves extract inhibited the growth of all (100%) the tested bacteria, and the recorded MICs ranged from 256 to 1024 μ g/ml. Other samples showed very selective activity; their inhibitory activities were recorded on 26/29 (89.65%; *P. guajava* bark and *P. americana* leaves and bark), 25/29 (82.75%; *C. sinensis*), 23/29 (79.31%; *C. edulis*), 22/29 (75.86%; *C. sinensis*), 21/29 (72.41%; *M. indica* leaves and bark), and 11/29 (37.93%; *P. guajava* fruits). The lowest MIC value of 32 μ g/mL was recorded with the crude extract of *C. edulis* against *E. coli* AG102 and *K. pneumoniae* K2, as well as with the extract from bark of *M. indica* against *P. aeruginosa* PA01 and the extract of *C. sinensis* against *E. coli* W3110. Extract from *C. sinensis* displayed the best MBC (256 μ g/mL) value against *E. coli* ATCC8739.

3.3. Role of Efflux Pumps in the Susceptibility of Gram-Negative Bacteria to the Tested Plant Extracts. Fifteen of the studied MDR bacteria were also tested for their susceptibility to plant extracts in the presence of the PA β N at 30 μ g/ml. The results showed that when combined with extracts, PA β N improves the activity (decrease of MIC values) of *C. sinensis* on 11/15 (73.33%) tested MDR strains. EPI also improved the activity of other extracts against the selected bacteria (Table 3).

3.4. Effects of the Association of Extracts with Antibiotics. A preliminary study performed against *P. aeruginosa* PA124 allowed us to select six out of ten extracts at the appropriate subinhibitory concentrations of MIC/2 and MIC/4 for further studies. All the six extracts were combined separately to eight antibiotics (CIP, STP, CHL, ERY, KAN, TET, CEF, and

AMP) to evaluate their possible synergetic effects. The results summarized in Tables 4–9 showed that the synergic effects were noted with all the tested extracts with most of the tested antibiotics except β -lactams (CEF and AMP). At MIC/2, the extract from *M. indica* leaves showed synergistic effects with 7 of the 8 antibiotics (CIP, STP, CHL, ERY, KAN, TET, and AMP) (87.5%) against at least 70% MDR bacteria for each antibiotic. At that same MIC, *C. sinensis* extract improved the activity of all (8/8) tested antibiotics against at least 50% of the tested MDR bacteria. Synergies with FIC ranging from 0.5 to <0.007 were noted with the associations of each of the seven extracts with antibiotics. These low FIC values obtained in the majority of cases (FIC < 0.007 for associations of *M. indica* + β -lactams vis-à-vis almost all the bacterial strains and also with many other extracts with streptomycin against many bacterial strains) indicate that extracts have potentiated the activity of antibiotics vis-à-vis the studied bacteria.

4. Discussion

Chemical Composition of the Tested Plant Extracts. Phytochemical screening revealed the presence of several classes of secondary metabolites such as alkaloids, polyphenols, flavonoids, anthraquinones, coumarins, saponins, tannins, triterpenes, and steroids. Several in vitro experiments proved that molecules belonging to these classes were found active on pathogenic microorganisms [55].

Antibacterial Activity of the Tested Extracts. After several decades of antibiotic use, pathogenic bacteria of human and animal origin have reached alarming levels of resistance. The reduced efficacy and increasing toxicity of synthetic drugs further aggravate this problem. Scientists are thus directed to seek more active natural or organic molecules [14]. It is imperative in developing countries that effective and less expensive antibacterials should be developed to accommodate all patients, regardless of financial status, in order to eliminate some human factors that can cause MDR. Medicinal plants have known to possess antimicrobial properties against MDR phenotypes [48–50, 56–59] and differences observed between

TABLE 3: Minimal inhibitory concentration (MIC) in $\mu\text{g/mL}$ of methanol extracts from the studied plants and chloramphenicol.

(a)

Bacterial strains	Tested samples and MIC and MBC and MIC in the presence of PA β N in parenthesis ($\mu\text{g/mL}$)											
	<i>P. guajava</i> (leaves)			<i>P. guajava</i> (fruits)			<i>P. guajava</i> (bark)			<i>P. americana</i> (leaves)		
	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R
<i>Escherichia coli</i>												
ATCC8739	512	—	—	1024	—	—	1024	—	—	256	—	—
ATCC10536	512	—	—	1024	—	—	512	—	—	256	—	—
AG100	1024	—	—	1024	—	—	512	—	—	256	—	—
AG100A	256 (256)	—	—	512	—	—	1024	—	—	256 (256)	—	—
AG102	512 (512)	—	—	256	1024	4	1024	—	—	64 (16)	1024	8
AG100ATet	512 (128)	—	—	—	—	—	1024	—	—	512 (128)	—	—
MC4100	512	—	—	—	—	—	1024	—	—	512	—	—
W3110	1024	—	—	—	—	—	1024	—	—	256	—	—
<i>Enterobacter aerogenes</i>												
ATCC13048	256	—	—	1024	—	—	512	—	—	512	—	—
EA-CM64	512 (512)	—	—	—	—	—	1024	—	—	512 (512)	—	—
EA3	512	—	—	—	—	—	512	—	—	256	—	—
EA27	128 (128)	—	—	—	—	—	—	—	—	128 (256)	—	—
EA289	256 (128)	—	—	—	—	—	512	—	—	256 (256)	—	—
EA294	1024	—	—	—	—	—	—	—	—	256	—	8
EA298	1024 (1024)	—	—	—	—	—	—	—	—	128	1024	4
<i>Klebsiella pneumoniae</i>												
ATCC11296	1024	—	—	—	—	—	—	—	—	512	—	—
K2	512	—	—	1024	—	—	1024	—	—	256	—	—
K24	512	—	—	—	—	—	1024	—	—	512	—	—
KP55	1024 (1024)	—	—	1024	—	—	512	—	—	— (—)	—	—
KP63	256 (16)	—	—	—	—	—	512	—	—	128 (<8)	1024	8
<i>Providencia stuartii</i>												
ATCC29916	512	—	—	—	—	—	1024	—	—	—	—	—
ATCC299645	512	—	—	1024	—	—	1024	—	—	512	—	—
PS2636	512 (512)	—	—	512	1024	2	512	—	—	256 (256)	1024	4
NEA16	1024 (1024)	—	—	—	—	—	512	1024	2	1024 (512)	—	—
										256 (16)	1024	4

(a) Continued.

Bacterial strains	Tested samples and MIC and MBC and MIC in the presence of PAβN in parenthesis (μg/mL)											
	<i>P. guajava</i> (leaves)			<i>P. guajava</i> (fruits)			<i>P. guajava</i> (bark)			<i>P. americana</i> (leaves)		
	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R
<i>Enterobacter cloacae</i>												
BM47	256 (1024)	—	—	—	—	—	512	—	—	512 (512)	—	—
BM67	256 (256)	—	—	1024	—	—	512	—	—	512 (512)	—	—
ECCI69	512 (512)	—	—	—	—	—	512	—	—	1024 (1024)	—	—
<i>Pseudomonas aeruginosa</i>												
PA01	512	—	—	—	—	—	1024	—	—	—	—	—
PA124	1024 (1024)	—	—	—	—	—	1024	—	—	— (—)	—	—

R: MIC/MBC; —: MIC > 1024 or not detected; (): values in parenthesis are MIC of substance in the presence of PAβN at 30 μg/mL; values in bold are the best MIC values for the plant extracts.

(b)

Bacterial strains	Tested samples and MIC and MBC and MIC in the presence of PAβN in parenthesis (μg/mL)											
	<i>Citrus sinensis</i>			<i>M. indica</i> (leaves)			<i>M. indica</i> (bark)			<i>Camellia sinensis</i>		
	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R
<i>Escherichia coli</i>												
ATCC8739	64	256	4	—	—	—	256	—	—	512	—	—
ATCC10536	256	—	—	512	—	—	256	—	—	512	—	—
AG100	128	—	—	1024	—	—	—	—	—	512	—	—
AG100A	512 (256)	—	—	1024	—	—	— (—)	—	—	512 (256)	—	—
AG102	128 (<8)	1024	4	1024 (1024)	—	—	1024 (1024)	—	—	256 (256)	—	—
AG100ATet	512 (8)	—	—	1024 (1024)	—	—	— (—)	—	—	256 (256)	—	—
MC4100	64	—	—	1024	—	—	1024	—	—	1024	—	—
W3110	32	512	16	1024	—	—	1024	—	—	1024	—	—
<i>Enterobacter aerogenes</i>												
ATCC13048	512	1024	2	512	—	—	512	—	—	512	—	—
EA-CM64	— (16)	—	—	— (1024)	—	—	— (—)	—	—	— (—)	—	—
EA3	256	—	—	1024	—	—	512	—	—	1024	—	—
EA27	512 (256)	—	—	512 (256)	—	—	512 (256)	—	—	1024 (1024)	—	—
EA289	512 (<8)	—	—	— (—)	—	—	512 (—)	—	—	512 (64)	—	—
EA294	128	512	4	—	—	—	—	—	—	1024	—	—
EA298	128 (128)	512	4	— (—)	—	—	— (—)	—	—	512 (512)	—	—

(b) Continued.

Bacterial strains	Tested samples and MIC and MBC and MIC in the presence of PAβN in parenthesis (μg/mL)											
	Citrus sinensis			M. indica (leaves)			M. indica (bark)			Camellia sinensis		
	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R	MIC	MBC	R
<i>Klebsiella pneumoniae</i>												
ATCC1296	512	—	—	—	—	—	—	—	—	512	—	—
K2	128	—	—	1024	—	—	—	—	—	64	—	—
K24	—	—	—	1024	—	—	—	—	—	512	—	—
KP55	— (<8)	—	—	1024 (1024)	—	—	—	—	—	— (<8)	—	—
KP63	256 (<8)	—	—	1024 (1024)	—	—	—	—	—	256 (64)	—	—
<i>Providencia stuartii</i>												
ATCC29916	—	—	—	512	—	—	—	—	—	512	—	—
ATCC29945	—	—	—	1024	—	—	—	—	—	512	1024	8
PS2636	1024 (<8)	—	—	512 (512)	—	—	—	—	—	— (<8)	512	1
NEA16	128 (16)	1024	8	512 (512)	—	—	—	—	—	1024 (1024)	1024	8
<i>Enterobacter cloacae</i>												
BM47	256 (16)	—	—	512	—	—	—	—	—	1024 (1024)	—	—
BM67	512 (512)	—	—	1024	—	—	—	—	—	256 (256)	1024	—
ECCI69	512 (512)	—	—	— (<8)	—	—	—	—	—	512 (256)	—	—
<i>Pseudomonas aeruginosa</i>												
PA01	128	512	4	1024	—	—	—	—	—	512	—	—
PA124	— (1024)	—	—	1024 (512)	—	—	—	—	—	1024 (1024)	—	—

R: CMB/CMi; —: MIC > 1024 or not detected; (): values in parenthesis are MIC of substance in the presence of PAβN at 30 μg/mL; values in bold are the best MIC values for the plant extracts.

(c)

Bacterial strains	MIC	Chloramphenicol MBC	R
<i>Escherichia coli</i>			
ATTC8739	4	16	4
ATCCI0536	4	128	32
AG100	8	64	8
AG100A	64	—	—
AG102	64	256	4
AG100ATet	128	—	—
MC4100	8	64	8
W3110	8	256	32
<i>Enterobacter aerogenes</i>			
ATCCI3048	8	64	8
EA-CM64	128	—	—
EA3	32	256	8
EA27	128	—	—
EA289	256	—	—
EA294	8	128	16
EA298	32	64	2

(c) Continued.

Bacterial strains	MIC	Chloramphenicol MIC	R
<i>Klebsiella pneumoniae</i>			
ATCC11296	64	—	—
K2	32	128	4
K24	128	256	2
KP55	64	128	2
KP63	64	256	4
<i>Providencia stuartii</i>			
ATCC29916	128	—	—
ATCC299645	64	256	4
PS2636	128	—	—
NEAI6	32	256	8
<i>Enterobacter cloacae</i>			
BM47	256	—	—
BM67	128	—	—
ECCI69	—	256	—
<i>Pseudomonas aeruginosa</i>			
PA01	32	—	—
PAI24	256	—	—

R: CMB/CMi; —: MIC > 1024 or not detected; values in parenthesis are MIC of substance in the presence of PAβN at 30 µg/mL; values in bold are the best MIC values for the plant extracts.

TABLE 4: MIC of different antibiotics after the association of the extract of *Citrus sinensis* at MIC/2, MIC/4 against ten MDR bacteria strains.

Antibiotics ^a		Extract concentration	Bacterial strains and MIC (μg/mL) of antibiotics in the absence and presence of the extract ^b										
			PA124	AG102	AG100Atet	EA289	CM64	KP55	KP63	NEA16	PS2636	BM47	PBSS ^c (%)
CHL	0	128	8	128	256	256	32	32	16	64	128		
	MIC/2	32 (0.25) ^S	<2 (<0.25) ^S	32 (0.25) ^S	256 (1) ^I	64 (0.25) ^S	32 (1) ^I	4 (0.125) ^S	16 (1) ^I	16 (0.25) ^S	128 (1) ^I	60	
	MIC/4	128 (1) ^I	<2 (<0.25) ^S	128 (1) ^I	256 (1) ^I	128 (0.5) ^S	32 (1) ^I	4 (0.125) ^S	16 (1) ^I	64 (1) ^I	128 (1) ^I	30	
CIP	0	64	2	>64	>64	>64	2	<0.5	4	8	<0.5		
	MIC/2	16 (0.25) ^S	1 (0.5) ^S	>64 (≥1) ^I	64 (<1) ^S	16 (<0.25) ^S	1 (0.5) ^S	<0.5 (≤1) ^I	4 (1) ^I	<1 (<0.125) ^S	<0.5 (≤1) ^I	60	
	MIC/4	32 (0.5) ^S	1 (0.5) ^S	>64 (≥1) ^I	>64 (≥1) ^I	16 (<0.25) ^S	1 (0.5) ^S	<0.5 (≤1) ^I	4 (1) ^I	2 (0.25) ^S	<0.5 (≤1) ^I	50	
TET	0	16	16	32	64	4	32	2	4	2	32		
	MIC/2	4 (0.25) ^S	<1 (<0.062) ^S	64 (2) ^I	64 (1) ^I	1 (0.25) ^S	32 (1) ^I	2 (1) ^I	4 (1) ^I	<1 (<0.5) ^S	32 (1) ^I	40	
	MIC/4	8 (0.5) ^S	<1 (<0.062) ^S	64 (2) ^I	64 (1) ^I	1 (0.25) ^S	32 (1) ^I	2 (1) ^I	4 (1) ^I	<1 (<0.5) ^S	32 (1) ^I	40	
ERY	0	128	8	128	256	8	16	4	16	16	16		
	MIC/2	128 (1) ^I	<2 (<0.25) ^S	128 (1) ^I	256 (1) ^I	8 (1) ^I	16 (1) ^I	<2 (<0.5) ^S	16 (1) ^I	8 (0.5) ^S	16 (1) ^I	30	
	MIC/4	128 (1) ^I	<2 (<0.25) ^S	128 (1) ^I	256 (1) ^I	8 (1) ^I	16 (1) ^I	<2 (<0.5) ^S	16 (1) ^I	16 (1) ^I	16 (1) ^I	20	
KAN	0	128	4	8	32	32	32	<2	16	16	8		
	MIC/2	128 (1) ^I	<2 (<0.5) ^S	8 (1) ^I	16 (0.5) ^S	16 (0.5) ^S	32 (1) ^I	<2 (≤1) ^I	8 (0.5) ^S	16 (1) ^I	8 (1) ^I	50	
	MIC/4	128 (1) ^I	<2 (<0.5) ^S	8 (1) ^I	16 (0.5) ^S	16 (0.5) ^S	32 (1) ^I	<2 (≤1) ^I	8 (0.5) ^S	16 (1) ^I	8 (1) ^I	50	
STP	0	256	>256	>256	128	8	64	8	16	>256	64		
	MIC/2	32 (0.125) ^S	32 (≥0.125) ^S	<2 (≤0.007) ^S	128 (1) ^I	<2 (0.25) ^S	16 (0.25) ^S	<2 (<0.25) ^S	16 (1) ^I	<2 (≤0.007) ^S	32 (0.5) ^S	80	
	MIC/4	128 (0.5) ^S	128 (≥0.5) ^S	<2 (≤0.007) ^S	128 (1) ^I	8 (1) ^I	16 (0.25) ^S	<2 (<0.25) ^S	16 (1) ^I	4 (≥0.062) ^S	64 (1) ^I	60	
AMP	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256		
	MIC/2	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	50	
	MIC/4	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	256 (<1) ^S	<2 (≤0.007) ^S	<2 (≤0.007) ^S	>256 (≥1) ^I	50	
CEF	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256		
	MIC/2	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	<2 (≤0.007) ^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	10	
	MIC/4	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	256 (<1) ^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	10	

^a Antibiotics [TET: tetracycline, CIP: ciprofloxacin, STP: streptomycin, KAN: kanamycin, CHL: chloramphenicol, ERY: erythromycin, AMP: ampicillin, and CEF: cefepime]. ^b Bacterial strains: *Escherichia coli* [AG102, AG100Atet], *Pseudomonas aeruginosa* [PA124], *Enterobacter aerogenes* [CM64, EA27, EA289], *Klebsiella pneumoniae* [KP55, KP63], *Providencia stuartii* [NAE16], and *Enterobacter cloacae* [BM47]. ^c PBSS: percentage of bacteria strain on which synergism has been observed. Values in parenthesis are fractional inhibitory concentration (FIC) of the antibiotics after association with plants extract; S: synergy; I: indifference. The values in bold represent the cases of synergy between extract and antibiotic.

TABLE 5: MIC of different antibiotics after the association of the extract of *Coula edulis* at MIC/2, MIC/4 against ten MDR bacteria strains.

Antibiotics ^a	Extract concentration	Bacterial strains and MIC (μg/mL) of antibiotics in the absence and presence of the extract ^b									
		PA124	AG102	AG100Atet	EA289	CM64	KP55	KP63	NEA16	PS2636	PBSS ^c (%)
CHL	0	128	8	128	256	256	32	32	16	64	128
	MIC/2	64 (0.5)^S	<2 (<0.25)^S	128 (1) ^I	256 (1) ^I	64 (0.25)^S	32 (1) ^I	32 (1) ^I	16 (1) ^I	8 (0.125)^S	128 (1) ^I
	MIC/4	64 (0.5)^S	4 (0.5)^S	128 (1) ^I	256 (1) ^I	128 (0.5)^S	32 (1) ^I	32 (1) ^I	16 (1) ^I	8 (0.125)^S	128 (1) ^I
CIP	0	64	2	>64	>64	>64	2	<0.5	4	8	<0.5
	MIC/2	16 (0.25)^S	<0.5 (<0.25)^S	>64 (≥1) ^I	32 (<0.5)^S	64 (<1)^S	2 (1) ^I	<0.5 (≤1) ^I	<0.5 (<0.25)^S	<0.5 (<0.125)^S	<0.5 (≤1) ^I
	MIC/4	16 (0.25)^S	<0.5 (<0.25)^S	>64 (≥1) ^I	32 (<0.5)^S	64 (<1)^S	2 (1) ^I	<0.5 (≤1) ^I	<0.5 (<0.25)^S	<0.5 (<0.125)^S	<0.5 (≤1) ^I
TET	0	16	16	32	64	4	32	2	4	2	32
	MIC/2	16 (1) ^I	<1 (<0.062)^S	64 (2) ^I	64 (1) ^I	<0.5 (<0.25)^S	32 (1) ^I	2 (1) ^I	4 (1) ^I	<1 (<0.5)^S	32 (1) ^I
	MIC/4	16 (1) ^I	<1 (<0.062)^S	64 (2) ^I	64 (1) ^I	<0.5 (<0.25)^S	32 (1) ^I	2 (1) ^I	4 (1) ^I	<1 (<0.5)^S	32 (1) ^I
ERY	0	128	8	128	256	8	16	4	16	16	16
	MIC/2	128 (1) ^I	<2 (<0.25)^S	128 (1) ^I	256 (1) ^I	16 (2) ^I	16 (1) ^I	4 (1) ^I	8 (0.5)^S	8 (0.5)^S	16 (1) ^I
	MIC/4	128 (1) ^I	<2 (<0.25)^S	128 (1) ^I	256 (1) ^I	16 (2) ^I	16 (1) ^I	4 (1) ^I	8 (0.5)^S	16 (1) ^I	16 (1) ^I
KAN	0	128	4	8	32	32	32	<2	16	16	8
	MIC/2	128 (1) ^I	<2 (<0.5)^S	8 (1) ^I	32 (1) ^I	32 (1) ^I	32 (1) ^I	<2 (≤1) ^I	16 (1) ^I	16 (1) ^I	8 (1) ^I
	MIC/4	128 (1) ^I	<2 (<0.5)^S	8 (1) ^I	32 (1) ^I	32 (1) ^I	32 (1) ^I	<2 (≤1) ^I	16 (1) ^I	16 (1) ^I	8 (1) ^I
STP	0	256	>256	>256	128	8	64	8	16	>256	64
	MIC/2	64 (0.25)^S	8 (<0.031)^S	<2 (≤0.007)^S	128 (1) ^I	128 (16) ^A	64 (1) ^I	8 (1) ^I	16 (1) ^I	8 (<0.031)^S	64 (1) ^I
	MIC/4	64 (0.25)^S	>256 (≥1) ^I	64 (<0.25)^S	128 (1) ^I	128 (16) ^A	64 (1) ^I	8 (1) ^I	16 (1) ^I	128 (<0.5)^S	64 (1) ^I
AMP	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256
	MIC/2	256 (<1)^S	<2 (≤0.007)^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	<2 (≤0.007)^S	<2 (≤0.007)^S	>256 (≥1) ^I
	MIC/4	>256 (≥1) ^I	<2 (≤0.007)^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	<2 (≤0.007)^S	<2 (≤0.007)^S	>256 (≥1) ^I
CEF	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256
	MIC/2	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I
	MIC/4	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I

^a Antibiotics [TET: tetracycline, CIP: ciprofloxacin, STP: streptomycin, KAN: kanamycin, CHL: chloramphenicol, ERY: erythromycin, AMP: ampicillin, and CEF: cefepime]. ^b Bacterial strains: *Escherichia coli* [AG102, AG100Atet], *Pseudomonas aeruginosa* [PA124], *Enterobacter aerogenes* [CM64, EA27, EA289], *Klebsiella pneumoniae* [KP55, KP63], *Providencia stuartii* [NAE16], and *Enterobacter cloacae* [BM47]. ^c PBSS: percentage of bacteria strain on which synergism has been observed. Values in parenthesis are fractional inhibitory concentration (FIC) of the antibiotics after association with plants extract; S: synergy; I: indifference; A: antagonism. The values in bold represent the cases of synergy between extract and antibiotic.

TABLE 6: MIC of different antibiotics after the association of the extract of leaves from *Mangifera indica* at MIC/2, MIC/4 against ten MDR bacteria strains.

Antibiotics ^a		Extract concentration	Bacterial strains and MIC (μg/mL) of antibiotics in the absence and presence of the extract ^b										
			PA124	AG102	AG100Atet	EA289	CM64	KP55	KP63	NEA16	PS2636	BM47	PBSS ^c (%)
CHL	0	128	8	128	256	256	32	32	16	64	128		
	MIC/2	32 (0.25) ^S	<2 (<0.25) ^S	4 (0.031) ^S	64 (0.25) ^S	128 (0.5) ^S	4 (0.125) ^S	8 (0.25) ^S	4 (0.25) ^S	16 (0.25) ^S	32 (0.25) ^S	100	
	MIC/4	32 (0.25) ^S	4 (0.5) ^S	4 (0.031) ^S	128 (0.5) ^S	128 (0.5) ^S	32 (1) ^I	32 (1) ^I	8 (0.5) ^S	64 (1) ^I	128 (1) ^I	60	
CIP	0	64	2	>64	>64	>64	2	<0.5	4	8	<0.5		
	MIC/2	32 (0.5) ^S	<0.5 (<0.25) ^S	8 (<0.125) ^S	2 (<0.031) ^S	64 (<1) ^S	2 (1) ^I	<0.5 (≥1) ^I	<0.5 (<0.125) ^S	<0.5 (<0.062) ^S	<0.5 (≥1) ^I	70	
	MIC/4	32 (0.5) ^S	<0.5 (<0.25) ^S	>64 (≥1) ^I	2 (<0.031) ^S	64 (<1) ^S	2 (1) ^I	<0.5 (≥1) ^I	2 (0.5) ^S	4 (0.5) ^S	<0.5 (≥1) ^I	60	
TET	0	16	16	32	64	4	32	2	4	2	32		
	MIC/2	32 (2) ^I	4 (0.25) ^S	8 (0.25) ^S	<2 (<0.031) ^S	2 (0.5) ^S	8 (0.25) ^S	1 (0.5) ^S	<0.5 (<0.125) ^S	<0.5 (<0.25) ^S	8 (0.25) ^S	90	
	MIC/4	32 (2) ^I	8 (0.5) ^S	16 (0.5) ^S	16 (0.25) ^S	2 (0.5) ^S	8 (0.25) ^S	1 (0.5) ^S	<0.5 (<0.125) ^S	<0.5 (<0.25) ^S	16 (0.5) ^S	90	
ERY	0	128	8	128	256	8	16	4	16	16	16		
	MIC/2	128 (1) ^I	<2 (<0.25) ^S	32 (0.25) ^S	32 (0.125) ^S	4 (0.5) ^S	8 (0.5) ^S	<2 (<0.5) ^S	4 (0.25) ^S	<2 (<0.125) ^S	<2 (<0.125) ^S	90	
	MIC/4	128 (1) ^I	<2 (<0.25) ^S	32 (0.25) ^S	128 (0.5) ^S	4 (0.5) ^S	16 (1) ^I	<2 (<0.5) ^S	8 (0.5) ^S	4 (0.25) ^S	4 (0.25) ^S	80	
KAN	0	128	4	8	32	32	32	<2	16	16	8		
	MIC/2	128 (1) ^I	<2 (<0.5) ^S	4 (0.5) ^S	<2 (<0.062) ^S	8 (0.25) ^S	4 (0.125) ^S	<2 (≥1) ^I	<2 (<0.125) ^S	4 (0.25) ^S	8 (1) ^I	70	
	MIC/4	128 (1) ^I	<2 (<0.5) ^S	8 (1) ^I	8 (0.25) ^S	16 (0.5) ^S	4 (0.125) ^S	<2 (≥1) ^I	8 (0.5) ^S	16 (1) ^I	8 (1) ^I	50	
STP	0	256	>256	>256	128	8	64	8	16	>256	64		
	MIC/2	128 (0.5) ^S	16 (<0.062) ^S	16 (<0.062) ^S	32 (0.25) ^S	4 (0.5) ^S	32 (0.5) ^S	4 (0.5) ^S	4 (0.25) ^S	64 (<0.5) ^S	4 (0.062) ^S	100	
	MIC/4	128 (0.5) ^S	32 (<0.125) ^S	16 (<0.062) ^S	64 (0.5) ^S	8 (1) ^I	32 (0.5) ^S	8 (1) ^I	16 (1) ^I	>256 (na)	8 (0.125) ^S	60	
AMP	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256		
	MIC/2	256 (<1) ^S	128 (<0.5) ^S	128 (<0.5) ^S	128 (<0.5) ^S	128 (<0.5) ^S	256 (<1) ^S	8 (<0.031) ^S	256 (<1) ^S	128 (<0.5) ^S	>256 (≥1) ^I	90	
	MIC/4	>256 (≥1) ^I	256 (<1) ^S	256 (<1) ^S	256 (<1) ^S	256 (<1) ^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	40	
CEF	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256		
	MIC/2	256 (<1) ^S	256 (<1) ^S	>256 (≥1) ^I	256 (<1) ^S	128 (<0.5) ^S	>256 (≥1) ^I	>256 (≥1) ^I	256 (<1) ^S	>256 (≥1) ^I	>256 (≥1) ^I	50	
	MIC/4	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	256 (<1) ^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	10	

^a Antibiotics [TET: tetracycline, CIP: ciprofloxacin, STP: streptomycin, KAN: kanamycin, CHL: chloramphenicol, ERY: erythromycin, AMP: ampicillin, and CEF: cefepime]. ^b Bacterial strains: *Escherichia coli* [AG102, AG100Atet], *Pseudomonas aeruginosa* [PA124], *Enterobacter aerogenes* [CM64, EA27, EA289], *Klebsiella pneumoniae* [KP55, KP63], *Providencia stuartii* [NAE16], and *Enterobacter cloacae* [BM47]. ^c PBSS: percentage of bacteria strain on which synergism has been observed. Values in parenthesis are fractional inhibitory concentration (FIC) of the antibiotics after association with plants extract; S: synergy; I: indifference. The values in bold represent the cases of synergy between extract and antibiotic.

TABLE 7: MIC of different antibiotics after the association of the extract of leaves from *Psidium guajava* at MIC/2, MIC/4 against ten MDR bacteria strains.

Antibiotics ^a	Concentration of the extract	Bacterial strains and MIC (μg/mL) of antibiotics in the absence and presence of the extract ^b										
		PA124	AG102	AG100Atet	EA289	CM64	KP55	KP63	NEA16	PS2636	BM47	PBSS ^c (%)
CHL	0	128	8	128	256	256	32	32	16	64	128	
	MIC/2	32 (0.25) ^S	4 (0.5) ^S	64 (0.5) ^S	256 (1) ^I	256 (1) ^I	32 (1) ^I	16 (0.5) ^S	8 (0.5) ^S	32 (0.25) ^S	32 (0.25) ^S	70
	MIC/4	32 (0.25) ^S	8 (1) ^I	128 (1) ^I	256 (1) ^I	256 (1) ^I	32 (1) ^I	32 (1) ^I	16 (1) ^I	64 (1) ^I	128 (1) ^I	10
CIP	0	64	4	>64	>64	>64	2	<0.5	4	8	<0.5	
	MIC/2	32 (0.5) ^S	4 (1) ^I	>64 (≥1) ^I	16 (<0.25) ^S	64 (<1) ^S	2 (1) ^I	<0.5 (≥1) ^I	2 (0.5) ^S	1 (0.125) ^S	<0.5 (≥1) ^I	50
	MIC/4	32 (0.5) ^S	4 (1) ^I	>64 (≥1) ^I	>64 (≥1) ^I	64 (<1) ^S	2 (1) ^I	<0.5 (≥1) ^I	4 (1) ^I	4 (0.5) ^S	<0.5 (≥1) ^I	30
TET	0	16	16	32	64	4	32	2	4	2	32	
	MIC/2	32 (2) ^I	4 (0.25) ^S	32 (1) ^I	32 (0.5) ^S	4 (1) ^I	16 (0.5) ^S	<0.5 (<0.25) ^S	<0.5 (<0.125) ^S	<0.5 (<0.25) ^S	16 (0.5) ^S	70
	MIC/4	32 (2) ^I	16 (1) ^I	32 (1) ^I	32 (0.5) ^S	4 (1) ^I	32 (1) ^I	1 (0.5) ^S	4 (1) ^I	<0.5 (<0.25) ^S	32 (1) ^I	30
ERY	0	128	8	128	256	8	16	4	16	16	16	
	MIC/2	128 (1) ^I	4 (0.5) ^S	128 (1) ^I	128 (0.5) ^S	<2 (<0.25) ^S	16 (1) ^I	2 (0.5) ^S	16 (1) ^I	16 (1) ^I	16 (0.5) ^S	50
	MIC/4	128 (1) ^I	4 (0.5) ^S	128 (1) ^I	128 (0.5) ^S	<2 (<0.25) ^S	16 (1) ^I	4 (1) ^I	16 (1) ^I	16 (1) ^I	16 (1) ^I	10
KAN	0	128	4	8	32	32	32	<2	16	16	8	
	MIC/2	128 (1) ^I	<2 (<0.5) ^S	8 (1) ^I	4 (0.5) ^S	32 (1) ^I	8 (0.25) ^S	<2 (≥1) ^I	8 (0.5) ^S	4 (0.25) ^S	8 (1) ^I	50
	MIC/4	128 (1) ^I	<2 (<0.5) ^S	8 (1) ^I	32 (1) ^I	32 (1) ^I	32 (1) ^I	<2 (≥1) ^I	8 (0.5) ^S	16 (1) ^I	8 (1) ^I	20
STP	0	256	>256	>256	128	8	64	8	16	>256	64	
	MIC/2	128 (0.5) ^S	16 (<0.062) ^S	128 (<0.5) ^S	128 (1) ^I	4 (0.5) ^S	64 (1) ^I	4 (0.5) ^S	16 (1) ^I	128 (<0.5) ^S	16 (0.25) ^S	70
	MIC/4	128 (0.5) ^S	128 (<0.5) ^S	256 (<1) ^S	128 (1) ^I	8 (1) ^I	64 (1) ^I	8 (1) ^I	16 (1) ^I	>256 (≥1) ^I	16 (0.25) ^S	40
AMP	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256	
	MIC/2	256 (<1) ^S	>256 (≥1) ^I	>256 (≥1) ^I	256 (<1) ^S	128 (<0.5) ^S	>256 (≥1) ^I	128 (<0.5) ^S	>256 (≥1) ^I	256 (<1) ^S	>256 (≥1) ^I	50
	MIC/4	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	10
CEF	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256	
	MIC/2	256 (<1) ^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	10
	MIC/4	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	00

^a Antibiotics [TET: tetracycline, CIP: ciprofloxacin, STP: streptomycin, KAN: kanamycin, CHL: chloramphenicol, ERY: erythromycin, AMP: ampicillin, and CEF: cefepime]. ^b Bacterial strains: *Escherichia coli* [AG102, AG100Atet], *Pseudomonas aeruginosa* [PA124], *Enterobacter aerogenes* [CM64, EA27, EA289], *Klebsiella pneumoniae* [KP55, KP63], *Providencia stuartii* [NAE16], and *Enterobacter cloacae* [BM47]. ^c PBSS: percentage of bacteria strain on which synergism has been observed. Values in parenthesis are fractional inhibitory concentration (FIC) of the antibiotics after association with plants extract; S: synergy; I: indifference. The values in bold represent the cases of synergy between extract and antibiotic.

TABLE 8: MIC of different antibiotics after the association of the extract of *Camellia sinensis* at MIC/2, MIC/4 against ten MDR bacteria strains.

Bacterial strains and MIC (μg/mL) of antibiotics in the absence and presence of the extract ^b												
Antibiotics ^a	Extract concentration	PA124	AG102	AG100Atet	EA289	CM64	KP55	KP63	NEA16	PS2636	BM47	PBSS ^c (%)
CHL	0	128	8	128	256	256	32	32	16	64	128	
	MIC/2	8 (0.0625)^S	<2 (<0.25)^S	64 (0.5)^S	128 (0.5)^S	64 (0.25)^S	8 (0.25)^S	16 (0.5)^S	<2 (<0.125)^S	4 (0.25)^S	16 (0.25)^S	100
	MIC/4	8 (0.0625)^S	<2 (<0.25)^S	64 (0.5)^S	256 (1) ^I	128 (0.5)^S	16 (0.5)^S	16 (0.5)^S	8 (0.5)^S	64 (1) ^I	128 (1) ^I	70
CIP	0	64	4	>64	>64	>64	2	<0.5	4	8	<0.5	
	MIC/2	32 (0.5)^S	<0.5 (<0.125)^S	16 (<0.25)^S	>64 (≥1) ^I	16 (<0.25)^S	<0.5 (<0.25)^S	<0.5 (<0.25)^S	<0.5 (<0.125)^S	<0.5 (<0.062)^S	<0.5 (≥1)^I	70
	MIC/4	32 (0.5)^S	<0.5 (<0.125)^S	>64 (≥1) ^I	>64 (≥1) ^I	16 (<0.25)^S	<0.5 (<0.25)^S	<0.5 (≥1)^I	4 (1) ^I	2 (0.25)^S	<0.5 (≥1)^I	50
TET	0	16	16	32	64	4	32	2	4	2	32	
	MIC/2	16 (1) ^I	<1 (<0.062)^S	8 (0.25)^S	16 (0.25)^S	2 (0.5)^S	32 (1) ^I	1 (0.5)^S	<0.5 (<0.125)^S	<0.5 (<0.25)^S	16 (0.5)^S	80
	MIC/4	16 (1) ^I	<1 (<0.062)^S	16 (0.5)^S	32 (0.5)^S	4 (1) ^I	32 (1) ^I	2 (1) ^I	<0.5 (<0.125)^S	<0.5 (<0.25)^S	32 (1) ^I	50
ERY	0	128	8	128	256	8	16	4	16	16	16	
	MIC/2	128 (1) ^I	<2 (<0.25)^S	32 (0.25)^S	64 (0.25)^S	<2 (<0.125)^S	16 (1) ^I	4 (1) ^I	4 (0.25)^S	4 (0.25)^S	<2 (<0.125)^S	70
	MIC/4	128 (1) ^I	4 (0.5)^S	64 (0.5)^S	64 (0.25)^S	<2 (<0.125)^S	16 (1) ^I	4 (1) ^I	8 (0.5)^S	4 (0.25)^S	4 (0.25)^S	70
KAN	0	128	4	8	32	32	32	<2	16	16	8	
	MIC/2	64 (0.5)^S	<2 (<0.5)^S	4 (0.5)^S	16 (0.5)^S	8 (0.25)^S	32 (1) ^I	<2 (≥1)^I	<0.5 (<0.031)^S	16 (1) ^I	8 (1) ^I	60
	MIC/4	64 (0.5)^S	<2 (<0.5)^S	8 (1) ^I	16 (0.5)^S	16 (0.5)^S	32 (1) ^I	<2 (≥1)^I	8 (0.5)^S	16 (1) ^I	8 (1) ^I	50
STP	0	256	>256	>256	128	8	64	8	16	>256	64	
	MIC/2	64 (0.25)^S	32 (<0.125)^S	128 (<0.5)^S	64 (0.5)^S	4 (0.5)^S	64 (1) ^I	<2 (<0.25)^S	<2 (<0.125)^S	64 (<0.25)^S	4 (0.0625)^S	90
	MIC/4	64 (0.25)^S	64 (<0.25)^S	128 (<0.5)^S	64 (0.5)^S	8 (1) ^I	64 (1) ^I	8 (1)^I	8 (0.5)^S	64 (<0.25)^S	16 (0.25)^S	70
AMP	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256	
	MIC/2	>256 (≥1) ^I	128 (<0.5)^S	128 (<0.5)^S	64 (<0.25)^S	128 (<0.5)^S	>256 (≥1) ^I	64 (<0.25)^S	128 (<0.5)^S	>256 (≥1) ^I	128 (<0.5)^S	70
	MIC/4	>256 (≥1) ^I	128 (<0.5)^S	>256 (≥1) ^I	256 (<1)^S	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	20
CEF	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256	
	MIC/2	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	128 (<0.5)^S	>256 (≥1) ^I	>256 (≥1) ^I	128 (<0.5)^S	256 (<0.5)^S	128 (<0.5)^S	128 (<0.5)^S	50
	MIC/4	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	>256 (≥1) ^I	00

^a Antibiotics [TET: tetracycline, CIP: ciprofloxacin, STP: streptomycin, KAN: kanamycin, CHL: chloramphenicol, ERY: erythromycin, AMP: ampicillin, and CEF: cefepime]. ^b Bacterial strains: *Escherichia coli* [AG102, AG100Atet], *Pseudomonas aeruginosa* [PA124], *Enterobacter aerogenes* [CM64, EA27, EA289], *Klebsiella pneumoniae* [KP55, KP63], *Providencia stuartii* [NAE16], and *Enterobacter cloacae* [BM47]. ^c PBSS: percentage of bacteria strain on which synergism has been observed. Values in parenthesis are fractional inhibitory concentration (FIC) of the antibiotics after association with plants extract; S: synergy; I: indifference; A: antagonism. The values in bold represent the cases of synergy between extract and antibiotic.

TABLE 9: MIC of different antibiotics after the association of the extract of bark from *Persea americana* at MIC/2, MIC/4 against ten MDR bacteria strains.

Antibiotics ^a	Extract concentration	Bacterial strains and MIC ($\mu\text{g/mL}$) of antibiotics in the absence and presence of the extract ^b										
		PA124	AG102	AG100Atet	EA289	CM64	KP55	KP63	NEA16	PS2636	BM47	PBSS ^c (%)
CHL	0	128	8	128	256	256	32	32	16	64	128	
	MIC/2	64 (0.5)^S	4 (0.5)^S	128 (1) ^I	256 (1) ^I	256 (1) ^I	32 (1) ^I	16 (0.5)^S	16 (1) ^I	64 (1) ^I	64 (0.5)^S	40
	MIC/4	64 (0.5)^S	8 (1) ^I	128 (1) ^I	256 (1) ^I	256 (1) ^I	32 (1) ^I	16 (0.5)^S	16 (1) ^I	64 (1) ^I	128 (1) ^I	20
CIP	0	64	8	>64	>64	>64	2	<0.5	4	8	<0.5	
	MIC/2	32 (0.5)^S	4 (0.5)^S	>64 (≥ 1) ^I	>64 (≥ 1) ^I	32 (<0.5)^S	<0.5 (<0.25)^S	<0.5 (≥ 1) ^I	4 (1) ^I	8 (1) ^I	<0.5 (≥ 1) ^I	40
	MIC/4	32 (0.5)^S	8 (1) ^I	>64 (≥ 1) ^I	>64 (≥ 1) ^I	>64 (≥ 1) ^I	<0.5 (<0.25)^S	<0.5 (≥ 1) ^I	4 (1) ^I	8 (1) ^I	<0.5 (≥ 1) ^I	20
TET	0	16	16	32	64	4	32	2	4	2	32	
	MIC/2	8 (0.5)^S	<1 (< 0.062) ^S	64 (2) ^I	32 (0.5)^S	<0.5 (<0.125)^S	16 (0.5)^S	1 (0.5)^S	<0.5 (<0.125)^S	2 (1) ^I	32 (1) ^I	70
	MIC/4	8 (0.5)^S	<1 (< 0.062) ^S	64 (2) ^I	32 (0.5)^S	<0.5 (<0.125)^S	32 (1) ^I	2 (1) ^I	4 (1) ^I	2 (1) ^I	32 (1) ^I	40
ERY	0	128	8	128	256	8	16	4	16	16	16	
	MIC/2	128 (1) ^I	4 (0.5)^S	16 (0.5)^S	128 (0.5)^S	8 (1) ^I	4 (0.5)^S	4 (1) ^I	16 (1) ^I	16 (1) ^I	8 (0.5)^S	50
	MIC/4	128 (1) ^I	8 (1) ^I	128 (1) ^I	128 (0.5)^S	8 (1) ^I	16 (1) ^I	4 (1) ^I	16 (1) ^I	16 (1) ^I	8 (0.5)^S	20
KAN	0	128	4	8	32	32	32	<2	16	16	8	
	MIC/2	128 (1) ^I	4 (1) ^I	4 (0.5)^S	32 (1) ^I	16 (0.5)^S	8 (0.25)^S	<2 (≥ 1) ^I	16 (1) ^I	4 (0.25)^S	8 (1) ^I	40
	MIC/4	128 (1) ^I	4 (1) ^I	8 (1) ^I	32 (1) ^I	16 (0.5)^S	16 (0.5)^S	<2 (≥ 1) ^I	16 (1) ^I	16 (1) ^I	8 (1) ^I	20
STP	0	256	>256	>256	128	8	64	8	16	>256	64	
	MIC/2	64 (0.25)^S	256 (<1)^S	>256 (≥ 1) ^I	128 (1) ^I	4 (0.5)^S	64 (1) ^I	4 (0.5)^S	16 (1) ^I	256 (<1)^S	32 (0.5)^S	60
	MIC/4	64 (0.25)^S	>256 (≥ 1) ^I	>256 (≥ 1) ^I	128 (1) ^I	8 (1) ^I	64 (1) ^I	8 (1) ^I	16 (1) ^I	>256 (≥ 1) ^I	32 (0.5)^S	20
AMP	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256	
	MIC/2	256 (<1)^S	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	128 (<0.5)^S	>256 (≥ 1) ^I	256 (<1)^S	>256 (≥ 1) ^I	30
	MIC/4	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	00
CEF	0	>256	>256	>256	>256	>256	>256	>256	>256	>256	>256	
	MIC/2	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	128 (<0.5)^S	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	10
	MIC/4	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	>256 (≥ 1) ^I	00

^a Antibiotics [TET: tetracycline, CIP: ciprofloxacin, STP: streptomycin, KAN: kanamycin, CHL: chloramphenicol, ERY: erythromycin, AMP: ampicillin, and CEF: cefepime]. ^b Bacterial strains: *Escherichia coli* [AG102, AG100Atet], *Pseudomonas aeruginosa* [PA124], *Enterobacter aerogenes* [CM64, EA27, EA289], *Klebsiella pneumoniae* [KP55, KP63], *Providencia stuartii* [NAE16], and *Enterobacter cloacae* [BM47]. ^c PBSS: percentage of bacteria strain on which synergism has been observed. Values in parenthesis are fractional inhibitory concentration (FIC) of the antibiotics after association with plants extract; S: synergy; I: indifference. The values in bold represent the cases of synergy between extract and antibiotic.

antibacterial activities of the extracts in the present study could be due to the differences in the composition as well as the mechanism of action of their bioactive compounds [55, 60]. Different solvents extracts of leaves from *P. guajava* have been separately documented to be inhibitory against both Gram-positive and Gram-negative bacteria [14, 15, 61]. In the present study, methanol extract from *P. guajava* leaf demonstrated significant inhibitory activities against both sensitive and MDR bacteria, confirming the previous reports on its antimicrobial activity. According to Kuete and Efferth [62], the antibacterial activity of a plant extract is considered significant when MIC values are below 100 µg/mL, moderate when $100 \leq \text{MICs} \leq 625$ µg/mL, and weak when MICs > 625 µg/mL. Consequently, the methanol *P. guajava* leaf extract tested herein had moderate activity. Besides, the activity (MIC of 32 and 64 µg/mL) observed with *C. edulis* nuts and *M. indica* bark as well as *C. sinensis* leaves extracts against *E. coli* AG102, *P. aeruginosa* PA01, and *K. pneumoniae* K2, respectively, can be considered important. The antibacterial activities of mango (*M. indica*) extracts against some microorganisms (Gram-positive and Gram-negative bacteria and *Candida albicans* yeast) have already been demonstrated [38, 63] and it is thought that the antibacterial activity of mango extract is due to the presence of gallotannin and mangiferin [64]. Different extracts of *C. sinensis* having antimicrobial activity were reported against Gram-positive and Gram-negative bacteria and fungi [65, 66] and it is thought that their antibacterial activities are due to the presence of catechin. In fact, catechin particularly affects the membrane fluidity in both hydrophilic and hydrophobic regions of lipid bilayers of the microorganism [67] or inhibits the action of DNA polymerases [68]. The present study provides additional data on the ability of this plant to fight MDR bacteria.

The leaves of *P. americana* are widely used for ethnomedicinal purposes worldwide. In order to confirm its multiple medicinal properties, a study conducted by Nathaniel et al. [18] showed that the methanolic extract from leaves of *P. americana* had good antimicrobial activity against enteric microorganisms (Gram-negative and Gram-positive bacteria and also yeasts). This is in accordance with the present study as we also found that methanol extracts of both leaves and bark of the plant exhibited similar activities against several MDR bacteria, with leaves' extract having good inhibitor effects (64 µg/mL) against the *E. coli* AG102 strain. Considering the fact that some of the tested plants are used as food with limited toxicity, the overall activity recorded with several extracts, most notably those of *C. sinensis*, *C. sinensis*, and *C. edulis* or the fruits from *P. guajava*, could be considered important. However, a threshold for significant antibacterial effects has been proposed for MIC values ranging within 100–512 µg/mL when samples tested are edible parts of plants [69].

Role of Efflux Pumps in the Susceptibility of Gram-Negative Bacteria to the Tested Extracts. The studied bacterial strains used in this work mostly resist by efflux mechanism, which consists in expelling all toxic compounds (including antibiotics) out of the cytoplasm, thus preventing them from

reaching their intracellular targets [70]. These efflux pumps can however be blocked competitively or not, in order to restore not only the intracellular concentration but also the activity of antibacterials acting on intracellular targets [71]. In the presence of PAβN (EPI), the antibacterial activity of *C. sinensis* extract was improved on 11/15 (73.37%) tested MDR strains. However, the antibacterial activities of other extracts were also improved on few selected bacteria. These results suggest that these extracts (*C. sinensis* especially) have an intracellular targets.

Effects of Association of Extracts with Antibiotics. The reduced efficiency of known antibiotics propels many researchers to search for novel compounds, as well as molecules capable of improving or at least restoring the efficiency of available antibiotics against resistant bacteria. The combination of both compounds can then help to prevent the emergence of resistant mutants and enable restoring the activity of antibiotics vis-à-vis resistant strains. Synergies with FIC ranging from 0.5 to <0.007 were noted with the associations of each of the extracts and antibiotics on at least one tested MDR bacteria. The extracts from leaves of *M. indica* and *C. sinensis* and also that from peels of *C. sinensis* had important synergistic effects with most of the tested antibiotics against the majority of bacteria. These results suggest that extracts inhibited the efflux pumps, increasing the activity of these antibiotics [72, 73]. Few cases of indifference ($1 \leq \text{FIC} < 4$) were found in the majority of associations; meanwhile antagonistic effect was obtained when *C. edulis* extract was combined with streptomycin against *E. aerogenes* EA-CM64 strain. All plants tested in the present study (Table 1) are used traditionally to treat several affections or diseases with symptoms related to microbial infections [8–10, 16, 17, 19, 20, 27, 29, 40], and data obtained therefore consolidate their traditional use. The presence of previously reported secondary metabolites in the tested plants [11, 12, 18, 21, 22, 27, 30, 31, 40, 41] (Table 1) is also in accordance with the present studies and could in part justify their antibacterial effects. Natural compounds belonging to terpenoids (for example, camosic acid and isopimarane derivatives), flavonoids (for example, 5'-methoxyhydnoicarpin) as well as alkaloids (for example, pheophorbide A or reserpine) and others have been identified as efflux pumps inhibitors [74, 75]. Extract from *M. indica* and *C. sinensis* having the best synergistic effects contain all these classes of secondary metabolites, probably explaining their antibiotic potentiation effects. These results could be explained by the interaction between active compounds of extracts and the active ingredients of antibiotics.

5. Limitations

Our study has limitations. It mainly reports the activity of crude plant extracts and the identification of the active constituents of the plant would be necessary for better understanding of the reported effects. Though this study deals with food plants, the cytotoxicity studies in normal cell lines will be performed to ascertain their safety.

6. Conclusion

The results of this study can provide some explanations on the traditional use of certain parts of the plants tested herein to combat infections, particularly those caused by enteric bacteria. Evidence of the antibacterial activity of the studied plants, especially edible ones, as well as the ability of some of them to improve the activity of commonly used antibiotics, is an indication that there is a possibility of discovering alternative antibacterials in these plants.

Abbreviations

AMP: Ampicillin
 ATCC: American type culture collection
 CEF: Cefepime
 CFU: Colony forming unit
 CHL: Chloramphenicol
 CIP: Ciprofloxacin
 DMSO: Dimethylsulfoxide
 EPI: Efflux pump inhibitor
 ERY: Erythromycin
 FIC: Fractional inhibitory concentration
 INT: p-Iodonitrotetrazolium chloride
 KAN: Kanamycin
 MDR: Multidrug-resistant
 MHB: Mueller-Hinton Broth
 MIC: Minimal inhibitory concentration
 PAßN: Phenylalanine-arginine- β -naphthylamide
 RND: Resistance nodulation-cell division
 STR: Streptomycin
 TET: Tetracycline.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Joachim K. Dzutam carried out the study; Victor Kuete designed the experiments. Joachim K. Dzutam and Victor Kuete wrote the manuscript; Victor Kuete supervised the work and provided the bacterial strains; all authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge the Cameroon National Herbarium for identification of plants.

References

- [1] S. B. Levy and T. F. O'Brien, "Global antimicrobial resistance alerts and implications," *Clinical Infectious Diseases*, vol. 41, no. 4, pp. S219–S220, 2005.
- [2] F. M. Aarestrup, "Veterinary drug usage and antimicrobial resistance in bacteria of animal origin," *Basic and Clinical Pharmacology and Toxicology*, vol. 96, no. 4, pp. 271–281, 2005.
- [3] K. Bush and G. H. Miller, "Bacterial enzymatic resistance: β -lactamases and aminoglycoside-modifying enzymes," *Current Opinion in Microbiology*, vol. 1, no. 5, pp. 509–515, 1998.
- [4] X. Z. Li and H. Nikaido, "Efflux-mediated drug resistance in bacteria: an update," *Drugs*, vol. 69, no. 12, pp. 1555–1623, 2009.
- [5] A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern, and J.-M. Pagès, "Antibiotic efflux pumps in Gram-negative bacteria: The inhibitor response strategy," *Journal of Antimicrobial Chemotherapy*, vol. 59, no. 6, pp. 1223–1229, 2007.
- [6] R. Verpoorte, "La Pharmacognosie du Nouveau Millénaire: Pistes et Biotechnologies. Des Sources du Savoir aux Médicaments du Futur," in *Proceedings of the 4th European Congress of Ethnopharmacology*, p. 274, IRD Edition, Paris, France, 2002.
- [7] J. D. D. Tamokou, M. F. Tala, H. K. Wabo, J. R. Kuiate, and P. Tane, "Antimicrobial activities of methanol extract and compounds from stem bark of *Vismia rubescens*," *Journal of Ethnopharmacology*, vol. 124, no. 3, pp. 571–575, 2009.
- [8] S. M. El Sohafy, A. M. Metwalli, F. M. Harraz, and A. A. Omar, "Quantification of flavonoids of *Psidium guajava* L. preparations by Planar Chromatography (HPTLC)," *Pharmacognosy Magazine*, vol. 4, no. 17, pp. 61–66, 2009.
- [9] S.-C. Shen, F.-C. Cheng, and N.-J. Wu, "Effect of guava (*Psidium guajava* linn.) leaf soluble solids on Glucose metabolism in type 2 diabetic rats," *Phytotherapy Research*, vol. 22, no. 11, pp. 1458–1464, 2008.
- [10] N. Nundkumar and J. A. O. Ojewole, "Studies on the antiparasitic properties of some South African medicinal plants used as antimalarial remedies in zulu folk medicine," *Methods and Findings in Experimental and Clinical Pharmacology*, vol. 24, no. 7, pp. 397–401, 2002.
- [11] A. A. T. Carvalho, M. C. C. Sampaio, A. F. M. Melo, F. C. Sampaio, K. X. F. R. Sena et al., "Atividade Antimicrobiana in Vitro de Extratos Hidroalcoólicos *Psidium guajava* L. Sobre Bactérias GramNegativas," *Acta Farmacêutica Bonaerense*, vol. 21, pp. 255–258, 2002.
- [12] K. Nisha, M. Darshana, G. Madhu, and M. K. Bhupendra, "GC-MS analysis and anti-microbial activity of *Psidium guajava* (leaves) grown in Malva region of India," *International Journal of Drug Development and Research*, vol. 3, no. 4, pp. 237–245, 2011.
- [13] W. C. Lee, R. Mahmud, S. Pillai, S. Perumal, and S. Ismail, "Antioxidant Activities of Essential Oil of *Psidium Guajava* L. Leaves," *APCBEE Procedia*, vol. 2, pp. 86–91, 2012.
- [14] D. L. Valle Jr., J. I. Andrade, J. J. M. Puzon, E. C. Cabrera, and W. L. Rivera, "Antibacterial activities of ethanol extracts of Philippine medicinal plants against multidrug-resistant bacteria," *Asian Pacific Journal of Tropical Biomedicine*, vol. 5, no. 7, pp. 532–540, 2015.
- [15] T. V. Braga, R. G. Does, C. S. Ramos et al., "Antioxidant, Antibacterial and Antitumor Activity of Ethanolic Extract of the *Psidium guajava* Leaves," *American Journal of Plant Sciences*, vol. 5, no. 23, pp. 3492–3500, 2014.
- [16] Q.-Y. Lu, J. R. Arteaga, Q. Zhang, S. Huerta, V. L. W. Go, and D. Heber, "Inhibition of prostate cancer cell growth by an avocado extract: role of lipid-soluble bioactive substances," *The Journal of Nutritional Biochemistry*, vol. 16, no. 1, pp. 23–30, 2005.
- [17] O. O. Adeyemi, S. O. Okpo, and O. O. Ogunti, "Analgesic and anti-inflammatory effects of the aqueous extract of leaves of *Persea americana* Mill (Lauraceae)," *Fitoterapia*, vol. 73, no. 5, pp. 375–380, 2002.

- [18] O. B. Nathaniel, A. S. Selina, K. M. John, B. Mercy, A. A. Sylvester, and B. M. Michael, "Phytoconstituents, antimicrobial and antioxidant properties of the leaves of *Persea americana* Mill cultivated in Ghana," *Journal of Medicinal Plants Research*, vol. 9, no. 36, pp. 933–939, 2015.
- [19] P. Milind and D. Chaturvede, "Orange: Range of benefits," *International Research Journal of Pharmacology*, vol. 3, pp. 59–63, 2012.
- [20] N. A. Adham, "Ethnobotanical evaluation of plants used in the traditional treatment of gastrointestinal disease in Erbil-Kurdistan region/Iraq," *World Journal of Pharmaceutical Sciences*, vol. 3, no. 9, pp. 1776–1781, 2015.
- [21] K. Ghasemi, Y. Ghasemi, and M. A. Ebrahimzadeh, "Antioxidant activity, phenol and flavonoid contents of 13 citrus species peels and tissues," *Pakistan Journal of Pharmaceutical Sciences*, vol. 22, no. 3, pp. 277–281, 2009.
- [22] F. Gülay Kirbaşlar, A. Tavman, B. Dülger, and G. Türker, "Antimicrobial activity of Turkish Citrus peel oils," *Pakistan Journal of Botany*, vol. 41, no. 6, pp. 3207–3212, 2009.
- [23] A. O. Kabra, G. B. Bairagi, A. S. Mahamuni, and R. S. Wanare, "In vitro antimicrobial activity and phytochemical analysis of the peels of *Citrus medica* L," in *Proceedings of the International Journal of Research in Pharmaceutical and Biomedical Sciences*, vol. 3, pp. 34–37, 2012.
- [24] H. M. Herath, M. D. Chamikara, D. R. Dissanayake et al., "A Comparative Assessment of the Antibacterial Activity in Fruit Juice of Sri Lankan Sweet Orange Cultivars vis a vis Sour Orange," *Journal of Agricultural Sciences*, vol. 11, no. 1, pp. 13–23, 2016.
- [25] M. Saïdani, W. Dhifi, and B. Marzouk, "Lipid evaluation of some Tunisian Citrus seeds," *Journal of Food Lipids*, vol. 11, no. 3, pp. 242–250, 2004.
- [26] J. Silalahi, "Anticancer and health protective properties of citrus fruit components," *Asia Pacific Journal of Clinical Nutrition*, vol. 11, no. 1, pp. 79–84, 2002.
- [27] B. C. Adebayo-Tayo and K. K. Ajibesin, "Antimicrobial Activities of *Coula edulis*," *Research Journal of Medicinal Plant*, vol. 2, no. 2, pp. 86–91, 2008.
- [28] D. Zofou, M. Tene, M. N. Ngemenya, P. Tane, and V. P. K. Titanji, "in Vitro antiplasmodial activity and cytotoxicity of extracts of selected medicinal plants used by traditional healers of western cameroon," *Malaria Research and Treatment*, p. 6, 2011.
- [29] G. M. M. Parvez, "Pharmacological activities of Mango (*Mangifera indica*): A Review," *Journal of Pharmacognosy and Phytochemistry*, vol. 5, no. 3, p. 1, 2016.
- [30] K. Mahattanatawee, J. A. Manthey, G. Luzio, S. T. Talcott, K. Goodner, and E. A. Baldwin, "Total antioxidant activity and fiber content of select Florida-grown tropical fruits," *Journal of Agricultural and Food Chemistry*, vol. 54, no. 19, pp. 7355–7363, 2006.
- [31] G. L. Pardo Andreu, R. Delgado, J. A. Velho, C. Curti, and A. E. Vercesi, "Mangiferin, a natural occurring glucosyl xanthone, increases susceptibility of rat liver mitochondria to calcium-induced permeability transition," *Archives of Biochemistry and Biophysics*, vol. 439, no. 2, pp. 184–193, 2005.
- [32] D. N. Muanza, K. L. Euler, L. Williams, and D. J. Newman, "Screening for antitumor and anti-HIV activities of nine medicinal plants from Zaire," *International Journal of Pharmacognosy*, vol. 33, no. 2, pp. 98–106, 1995.
- [33] Z.-G. Peng, J. Luo, L.-H. Xia, Y. Chen, and S.-J. Song, "CML cell line K562 cell apoptosis induced by mangiferin," *Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = Journal of experimental hematology/Chinese Association of Pathophysiology*, vol. 12, no. 5, pp. 590–594, 2004.
- [34] A. Bhowmik, L. A. Khan, M. Akhter, and B. Rokeya, "Studies on the antidiabetic effects of *Mangifera indica* stem-barks and leaves on nondiabetic, type 1 and type 2 diabetic model rats," *Bangladesh Journal of Pharmacology*, vol. 4, no. 2, pp. 110–114, 2009.
- [35] G. Bidla, V. P. K. Titanji, B. Joko, G. El-Ghazali, A. Bolad, and K. Berzins, "Antiplasmodial activity of seven plants used in African folk medicine," *Indian Journal of Pharmacology*, vol. 36, no. 4, pp. 245–246, 2004.
- [36] Z. Shabani and A. Sayadi, "The antimicrobial in vitro effects of different concentrations of some plant extracts including tamarisk, march, acetone and mango kernel," *Journal of Applied Pharmaceutical Science*, vol. 4, no. 5, pp. 75–79, 2014.
- [37] V. Vega-Vega, B. A. Silva-Espinoza, M. R. Cruz-Valenzuela et al., "Antimicrobial and antioxidant properties of by product extracts of mango fruit," *Journal of Applied Botany and Food Quality*, vol. 86, no. 1, pp. 205–211, 2013.
- [38] A. Sahrawat, S. Pal, and S. K. Shahi, "Antibacterial activity of *Mangifera indica* (mango) leaves against drug resistant bacterial strains," *International Journal of Advanced Research*, vol. 1, no. 6, pp. 82–86, 2013.
- [39] L. Tona, K. Kambu, N. Ngimbi et al., "Antiamoebic and spasmolytic activities of extracts from some anti-diarrhoeal traditional preparations used in Kinshasa, Congo," *Phytomedicine*, vol. 7, no. 1, pp. 31–38, 2000.
- [40] A. B. Sharangi, "Medicinal and therapeutic potentialities of tea (*Camellia sinensis* L.)—a review," *Food Research International*, vol. 42, no. 5–6, pp. 529–535, 2009.
- [41] P. M. Moderno, M. Carvalho, and B. M. Silva, "Recent patents on *Camellia sinensis*: source of health promoting compounds," *Recent Patents on Food, Nutrition & Agriculture*, vol. 1, no. 3, pp. 182–192, 2009.
- [42] E. W. C. Chan, Y. Y. Lim, and Y. L. Chew, "Antioxidant activity of *Camellia sinensis* leaves and tea from a lowland plantation in Malaysia," *Food Chemistry*, vol. 102, no. 4, pp. 1214–1222, 2007.
- [43] J. B. Harbone, *Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis*, Chapman and Hall Ltd., London, UK, 1973.
- [44] H. M. P. Poumale, R. Hamm, Y. Zang, Y. Shiono, and V. Kuete, "Coumarins and Related Compounds from the Medicinal Plants of Africa," *Medicinal Plant Research in Africa: Pharmacology and Chemistry*, pp. 261–300, 2013.
- [45] J. A. Seukep, A. G. Fankam, D. E. Djeussi et al., "Antibacterial activities of the methanol extracts of seven Cameroonian dietary plants against bacteria expressing MDR phenotypes," *SpringerPlus*, vol. 2, no. 1, pp. 1–8, 2013.
- [46] F. K. Touani, A. J. Seukep, D. E. Djeussi, A. G. Fankam, J. A. K. Noumedem, and V. Kuete, "Antibiotic-potential activities of four Cameroonian dietary plants against multidrug-resistant Gram-negative bacteria expressing efflux pumps," *BMC Complementary and Alternative Medicine*, vol. 14, article no. 258, 2014.
- [47] J. N. Eloff, "A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria," *Planta Medica*, vol. 64, no. 8, pp. 711–713, 1998.
- [48] V. Kuete, A. T. Mbaveng, M. Tsaffack et al., "Antitumor, antioxidant and antimicrobial activities of *Bersama engleriana* (Melianthaceae)," *Journal of Ethnopharmacology*, vol. 115, no. 3, pp. 494–501, 2007.

- [49] V. Kuete, G. F. Wabo, B. Ngameni et al., "Antimicrobial activity of the methanolic extract, fractions and compounds from the stem bark of *Irvingia gabonensis* (Ixonanthaceae)," *Journal of Ethnopharmacology*, vol. 114, no. 1, pp. 54–60, 2007.
- [50] V. Kuete, F. Nana, B. Ngameni, A. T. Mbaveng, F. Keumedjio, and B. T. Ngadjui, "Antimicrobial activity of the crude extract, fractions and compounds from stem bark of *Ficus ovata* (Moraceae)," *Journal of Ethnopharmacology*, vol. 124, no. 3, pp. 556–561, 2009.
- [51] A. G. Fankam, V. Kuete, I. K. Voukeng, J. R. Kuiate, and J.-M. Pages, "Antibacterial activities of selected Cameroonian spices and their synergistic effects with antibiotics against multidrug-resistant phenotypes," *BMC Complementary and Alternative Medicine*, vol. 11, p. 104, 2011.
- [52] I. K. Voukeng, V. Kuete, J. P. Dzoyem et al., "Antibacterial and antibiotic-potential activities of the methanol extract of some cameroonian spices against Gram-negative multi-drug resistant phenotypes," *BMC Research Notes*, vol. 5, p. 299, 2012.
- [53] L. C. Braga, A. A. M. Leite, K. G. S. Xavier et al., "Synergic interaction between pomegranate extract and antibiotics against *Staphylococcus aureus*," *Canadian Journal of Microbiology*, vol. 51, no. 7, pp. 541–547, 2005.
- [54] H. D. M. Coutinho, A. Vasconcellos, H. L. Freire-Pessôa, C. A. Gadelha, T. S. Gadelha, and G. G. Almeida-Filho, "Natural products from the termite *Nasutitermes corniger* lowers aminoglycoside minimum inhibitory concentrations," *Pharmacognosy Magazine*, vol. 6, no. 21, pp. 1–4, 2010.
- [55] M. M. Cowan, "Plant products as antimicrobial agents," *Clinical Microbiology Reviews*, vol. 12, no. 4, pp. 564–582, 1999.
- [56] V. Kuete, J. Kamga, L. P. Sandjo et al., "Antimicrobial activities of the methanol extract, fractions and compounds from *Ficus polita* Vahl. (Moraceae)," *BMC Complementary and Alternative Medicine*, vol. 11, article 6, 2011.
- [57] V. Kuete, B. Wiench, M. S. Alsaid et al., "Cytotoxicity, mode of action and antibacterial activities of selected Saudi Arabian medicinal plants," *BMC Complementary and Alternative Medicine*, vol. 13, p. 354, 2013.
- [58] S. B. Tankeo, P. Tane, and V. Kuete, "In vitro antibacterial and antibiotic-potential activities of the methanol extracts from *Beilschmiedia acuta*, *Clausena anisata*, *Newbouldia laevis* and *Polyscias fulva* against multidrug-resistant Gram-negative bacteria," *BMC Complementary and Alternative Medicine*, vol. 15, p. 412, 2015.
- [59] J. K. Dzotam, F. K. Touani, and V. Kuete, "Antibacterial and antibiotic-modifying activities of three food plants (*Xanthosoma mafaffa* Lam., *Moringa oleifera* (L.) Schott and *Passiflora edulis* Sims) against multidrug-resistant (MDR) Gram-negative bacteria," *BMC Complementary and Alternative Medicine*, vol. 16, no. 1, pp. 1–8, 2016.
- [60] A. R. Ndhlala, S. O. Amoo, B. Ncube, M. Moyo, J. J. Nair et al., "16 - Antibacterial, Antifungal, and Antiviral Activities of African Medicinal Plants," in *Kuete V, Medicinal Plant Research in Africa*, Ed., pp. 621–659, Elsevier, Oxford, UK, 2013.
- [61] O. E. Charles, A. A. Anthony, S. M. Kwaliafon, N. I. Nneka, and F. C. Kennedy, "Antimicrobial activity of *Psidium guajava* Linn. stem extracts against methicillin-resistant *Staphylococcus aureus*," *African Journal of Biotechnology*, vol. 11, no. 89, pp. 15556–15559, 2012.
- [62] V. Kuete and T. Efferth, "Cameroonian medicinal plants: Pharmacology and derived natural products," *Frontiers in Pharmacology*, vol. 1, p. 123, 2010.
- [63] I. Stoilova, S. Gargova, A. Stoyanova, and L. Ho, "Antimicrobial and antioxidant activity of the polyphenol mangiferin," *Herb Polonica*, vol. 51, pp. 37–44, 2005.
- [64] C. Engels, A. Schieber, and M. G. Gänzle, "Inhibitory spectra and modes of antimicrobial action of gallotannins from mango kernels (*Mangifera indica* L.)," *Applied and Environmental Microbiology*, vol. 77, no. 7, pp. 2215–2223, 2011.
- [65] S. Archana and J. Abraham, "Comparative analysis of antimicrobial activity of leaf extract from fresh green tea, commercial green tea and black tea on pathogens," *Journal of Applied Pharmaceutical Science*, vol. 1, no. 8, pp. 149–152, 2011.
- [66] P. Anita, I. Balan, S. Ethiraj, P. Madan Kumar, and S. Sivasamy, "In vitro antibacterial activity of *Camellia sinensis* extract against cariogenic microorganisms," *Journal of Basic and Clinical Pharmacy*, vol. 6, no. 1, pp. 35–39, 2015.
- [67] H. Tsuchiya, "Effects of green tea catechins on membrane fluidity," *Pharmacology*, vol. 59, no. 1, pp. 34–44, 2006.
- [68] S. M. Saleh, B. H. Saleh, and A. E. S. Bahjat, "Antimicrobial Activity of Water and Methanol Leaf Extracts of Green Tea (*Camellia Sinensis*) Against Some Pathogenic Bacteria," *Journal of Al-Nahrain University*, vol. 17, pp. 162–167, 2014.
- [69] J. D. D. Tamokou, A. T. Mbaveng, and V. Kuete, "Chapter 8 - Antimicrobial Activities of African Medicinal Spices and Vegetables," in *Medicinal Spices and Vegetables from Africa*, pp. 207–237, Kuete V: Academic Press, London, UK, 2017.
- [70] J. A. Bohnert and W. V. Kern, "Selected arylpiperazines are capable of reversing multidrug resistance in *Escherichia coli* overexpressing RND efflux pumps," *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 2, pp. 849–852, 2005.
- [71] N. Mesaros, F. Van Bambeke, Y. Glupczynski, R. Vanhoof, and P. M. Tulkens, "L'efflux des antibiotiques: un mécanisme ubiquitaire conduisant à la résistance. Etat de la question et implications microbiologiques et cliniques," *Louvain Medical*, vol. 124, no. 8, pp. 308–320, 2005.
- [72] V. Lorenzi, A. Muselli, A. F. Bernardini et al., "Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 5, pp. 2209–2211, 2009.
- [73] B. Zechini and I. Versace, "Inhibitors of multidrug resistant efflux systems in bacteria," *Recent Patents on Anti-Infective Drug Discovery*, vol. 4, no. 1, pp. 37–50, 2009.
- [74] B. Marquez, "Bacterial efflux systems and efflux pumps inhibitors," *Biochimie*, vol. 87, no. 12, pp. 1137–1147, 2005.
- [75] M. Ahmed, C. M. Borsch, A. A. Neyfakh, and S. Schuldiner, "Mutants of the *Bacillus subtilis* multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine," *Journal of Biological Chemistry*, vol. 268, no. 15, pp. 11086–11089, 1993.